Publications
Publications
Show Results For
-
All HBS Web
(113,651)
- Faculty Publications (26)
Page 1 of
26
Results
→
- 2023
- Working Paper
Evaluation and Learning in R&D Investment
By: Alexander P. Frankel, Joshua L. Krieger, Danielle Li and Dimitris Papanikolaou
We examine the role of spillover learning in shaping the value of exploratory versus incremental
R&D. Using data from drug development, we show that novel drug candidates generate more
knowledge spillovers than incremental ones. Despite being less likely to reach...
View Details
- September 2022
- Article
Find and Replace: R&D Investment Following the Erosion of Existing Products
By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first...
View Details
- 2022
- Working Paper
Are Transformational Ideas Harder to Fund? Resource Allocation to R&D Projects at a Global Pharmaceutical Firm
By: Joshua Krieger and Ramana Nanda
We study resource allocation to early-stage ideas at an internal startup program of one the largest pharmaceutical firms in the world. Our research design enables us to elicit every evaluator's scores across five different attributes, before seeing how would allocate...
View Details
- August 2022
- Teaching Note
AppHarvest: Rebuilding the Appalachian Economy Through Agriculture
By: Joshua Lev Krieger, William R. Kerr and Bailey McAfee
- August 2022
- Teaching Note
In-Q-Tel: Innovation On A Mission
By: Josh Lerner and Joshua Lev Krieger
Teaching Note for HBS Case No. 823-031.
View Details
- August 2022
- Case
In-Q-Tel: Innovation On A Mission
By: Joshua Lev Krieger and Josh Lerner
In 2022, the leaders of In-Q-Tel (IQT) considered what was next for the unique mission-driven organization. Since 1999, IQT had one mission: to be the most sophisticated source of strategic technical knowledge and capabilities to the U.S. government and its allies. IQT...
View Details
- March 2022
- Teaching Note
Tomorrow.io Goes To Space
By: Joshua Lev Krieger, Abhishek Nagaraj and James Barnett
Teaching Note for HBS Case No. 822-005. In March 2021, the weather company Tomorrow.io announced a new project to develop satellites equipped with radar for weather monitoring and launch them into Earth’s orbit. Company leadership considers execution strategies.
View Details
- March 2022
- Teaching Note
Biobot Analytics
- 2022
- Article
Missing Novelty in Drug Development
By: Joshua Krieger, Danielle Li and Dimitris Papanikolaou
We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We introduce a new measure of drug novelty based on chemical similarity and show that firms face a risk-reward trade-off: novel drug candidates are less likely to...
View Details
- January 2022
- Case
Tomorrow.io Goes To Space
By: Joshua Lev Krieger, Abhishek Nagaraj and James Barnett
In March 2021, the weather company Tomorrow.io announced a new project to develop satellites equipped with radar for weather monitoring and launch them into Earth’s orbit. Company leadership considers execution strategies.
View Details
- January 2022 (Revised March 2022)
- Teaching Note
Catalys Pacific
Teaching Note for HBS Case No. 821-035.
View Details
- November 2021 (Revised March 2022)
- Case
AppHarvest: Rebuilding the Appalachian Economy Through Agriculture
By: Joshua Lev Krieger, William R. Kerr and Christian Godwin
In 2021, AppHarvest completed construction of a 60-acre indoor farming facility, one of the world’s largest, recorded its first sales, and went public in a multi-billion dollar IPO. Described as “a force of nature,” Jonathan Webb founded the company to bring jobs back...
View Details
- September 2021
- Article
Trials and Terminations: Learning from Competitors' R&D Failures
I analyze project continuation decisions where firms may resolve uncertainty through news about competitors' research and development (R&D) failures, as well as through their own results. I examine the trade-offs and interactions between product-market competition and...
View Details
- 2022
- Working Paper
Standing on the Shoulders of Science
By: Joshua Lev Krieger, Monika Schnitzer and Martin Watzinger
Today's innovations rely on scientific discoveries of the past, yet only some corporate R&D builds directly on scientific output. In this paper, we analyze U.S. patents to investigate how firms generate value by building on prior art "closer" to science and establish...
View Details
- May 2021
- Article
Private and Social Returns to R&D: Drug Development and Demographics
By: Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou and Joshua Krieger
Investment in intangible capital such as R&D has increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...
View Details
- January 2021 (Revised June 2023)
- Case
Biobot Analytics
In 2017, Newsha Ghaeli and Mariana Matus were deciding whether to leave their labs at the Massachusetts Institute of Technology, put other job opportunities aside, and dive full-time into founding a wastewater analysis start-up, Biobot. Ghaeli, an architect, and Matus,...
View Details
- December 2020 (Revised March 2022)
- Teaching Note
Forecasting ClimaCell
By: Joshua Lev Krieger, Christopher Stanton and James Barnett
A weather technology startup, ClimaCell considers the R&D trade-offs and financing implications of pursuing a proposed contract with a major automobile maker, rather than continuing its focus on building a scalable, all-purpose weather prediction engine.
View Details
- September 2020 (Revised January 2021)
- Case
Catalys Pacific
In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After...
View Details
Keywords:
Pharmaceutical Companies;
Biotech;
Health Care;
Entrepreneur;
Innovation;
International Business;
Entrepreneurial Finance;
Entrepreneurship;
Finance;
Innovation Strategy;
Venture Capital;
Strategy;
Cross-Cultural and Cross-Border Issues;
Pharmaceutical Industry;
Biotechnology Industry;
Tokyo
- December 2019
- Case
Forecasting ClimaCell
By: Joshua Lev Krieger, Christopher Stanton and James Barnett
A weather technology startup, ClimaCell considers the R&D trade-offs and financing implications of pursuing a proposed contract with a major automobile maker, rather than continuing its focus on building a scalable, all-purpose weather prediction engine.
View Details
- 2020
- Working Paper
Trials and Terminations: Learning from Competitors' R&D Failures
I analyze project continuation decisions where firms may resolve uncertainty through news about competitors' research and development (R&D) failures, as well as through their own results. I examine the trade-offs and interactions between product-market competition and...
View Details